Skip to main content
. 2013 Jul 4;24(3):258–264. doi: 10.3802/jgo.2013.24.3.258

Fig. 1.

Fig. 1

Progression-free (A) and overall survival (B) from the initiation of bevacizumab and cylophosphamide between responders and non-responders.